Download PDF
Semin Liver Dis 2008; 28(4): 407-426
DOI: 10.1055/s-0028-1091985
© Thieme Medical Publishers

Role of Fatty Acids in the Pathogenesis of Obesity and Fatty Liver: Impact of Bariatric Surgery

Elizabeth C. Verna1 , Paul D. Berk1
  • 1Department of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, New York, New York
Further Information

Publication History

Publication Date:
27 October 2008 (online)

    Permissions and Reprints

ABSTRACT

Nonalcoholic fatty liver disease (NAFLD) spans a spectrum from simple steatosis to nonalcoholic steatohepatitis (NASH) to cirrhosis. Simple steatosis is the substrate upon which the more serious entities in the spectrum develop; it is the first “hit” in the multistep pathogenesis of NASH, which is considered the hepatic manifestation of the metabolic syndrome. Demonstration of the existence of regulatable fatty acid transport mechanisms has contributed to clarifying the role of fatty acid disposition in obesity, the various components of NAFLD, and the metabolic syndrome. Hepatic steatosis is closely linked to obesity. This linkage is based on the fact that obesity results in marked enlargement of the intraabdominal visceral fat depots. The eventual development of insulin resistance leads to continuous lipolysis within these depots, releasing fatty acids into the portal circulation, where they are rapidly translocated to the liver and reassembled into triglycerides. Reactive oxygen species, generated in the liver from oxidation of fatty acids, are precipitating factors in the cascade of events leading from simple steatosis to NASH. Dysregulation of fatty acid disposition, with ectopic lipid accumulation in other tissues, is a major contributing factor to other components of the metabolic syndrome. Bariatric surgery is an effective treatment for severe obesity, but its role in the management of the various forms of fatty liver disease is unclear. Our review of the literature that includes both initial and follow-up liver biopsies suggests that most obese patients with simple steatosis and NASH who undergo bariatric surgery will achieve improvement in hepatic histology, but that occasional patients, especially those who lose weight very rapidly, may show worsening of either fibrosis or steatohepatitis.

KEYWORDS

Obesity - type 2 diabetes mellitus - hepatic steatosis - nonalcoholic fatty liver disease - steatohepatitis - NAFLD - NASH

REFERENCES

  • 1 The Surgeon General's Call to Action to Prevent and Decrease Overweight and Obesity—2001. Washington, DC; Goverment Printing Office, U.S. Department of Health and Human Services 2001
    Google Scholar
  • 2 Yanovski S Z, Yanovski J A. Obesity.  N Engl J Med. 2002;  346(8) 591-602
    CrossrefPubMedGoogle Scholar
  • 3 Flegal K M, Carroll M D, Ogden C L, Johnson C L. Prevalence and trends in obesity among US adults, 1999–2000.  JAMA. 2002;  288(14) 1723-1727
    CrossrefPubMedGoogle Scholar
  • 4 Ogden C L, Yanovski S Z, Carroll M D, Flegal K M. The epidemiology of obesity.  Gastroenterology. 2007;  132(6) 2087-2102
    CrossrefPubMedGoogle Scholar
  • 5 State-specific prevalence of obesity among adults—United States, 2005.  MMWR Morb Mortal Wkly Rep. 2006;  55(36) 985-988
    PubMedGoogle Scholar
  • 6 Wanless I R, Lentz J S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors.  Hepatology. 1990;  12(5) 1106-1110
    CrossrefPubMedGoogle Scholar
  • 7 Clark J M, Brancati F L, Diehl A M. The prevalence and etiology of elevated aminotransferase levels in the United States.  Am J Gastroenterol. 2003;  98(5) 960-967
    CrossrefPubMedGoogle Scholar
  • 8 Ruhl C E, Everhart J E. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States.  Gastroenterology. 2003;  124(1) 71-79
    CrossrefPubMedGoogle Scholar
  • 9 Ruhl C E, Everhart J E. Epidemiology of nonalcoholic fatty liver.  Clin Liver Dis. 2004;  8(3) 501-519
    CrossrefPubMedGoogle Scholar
  • 10 Browning J D, Szczepaniak L S, Dobbins R et al.. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.  Hepatology. 2004;  40(6) 1387-1395
    CrossrefPubMedGoogle Scholar
  • 11 Clark J M. The epidemiology of nonalcoholic fatty liver disease in adults.  J Clin Gastroenterol. 2006;  40(suppl 1) S5-S10
    PubMedGoogle Scholar
  • 12 Kopelman P G. Obesity as a medical problem.  Nature. 2000;  404(6778) 635-643
    CrossrefPubMedGoogle Scholar
  • 13 Ogden C L, Carroll M D, Curtin L R, McDowell M A, Tabak C J, Flegal K M. Prevalence of overweight and obesity in the United States, 1999–2004.  JAMA. 2006;  295(13) 1549-1555
    CrossrefPubMedGoogle Scholar
  • 14 Ogden C L, McDowell M A, Flegal K M. Obesity among adults in the United States: no change since 2003–2004. NCHS Data Brief #1. Hyattsville, MD; National Center for Health Statistics 2007
    Google Scholar
  • 15 Danaei G, Vander Hoorn S, Lopez A D, Murray C J, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors.  Lancet. 2005;  366(9499) 1784-1793
    CrossrefPubMedGoogle Scholar
  • 16 Kleiner D E, Brunt E M, Van Natta M et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.  Hepatology. 2005;  41(6) 1313-1321
    CrossrefPubMedGoogle Scholar
  • 17 Bondini S, Kleiner D E, Goodman Z D, Gramlich T, Younossi Z M. Pathologic assessment of non-alcoholic fatty liver disease.  Clin Liver Dis. 2007;  11(1) 17-23
    CrossrefPubMedGoogle Scholar
  • 18 Yeh M M, Brunt E M. Pathology of nonalcoholic fatty liver disease.  Am J Clin Pathol. 2007;  128(5) 837-847
    CrossrefPubMedGoogle Scholar
  • 19 Brunt E M. Nonalcoholic steatohepatitis: definition and pathology.  Semin Liver Dis. 2001;  21(1) 3-16
    Article in Thieme ConnectPubMedGoogle Scholar
  • 20 Brunt E M, Neuschwander-Tetri B A, Oliver D, Wehmeier K R, Bacon B R. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens.  Hum Pathol. 2004;  35(9) 1070-1082
    CrossrefPubMedGoogle Scholar
  • 21 Brunt E M. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis.  Semin Diagn Pathol. 2005;  22(4) 330-338
    CrossrefPubMedGoogle Scholar
  • 22 Thung S N, Gerber M. Alcoholic hepatitis vs nonalcoholic steatohepatitis. In: Thung SN, Gerber MA Differential Diagnosis in Pathology: Liver Disorders. New York; Igaku-Shoin 1995: 24-36
    Google Scholar
  • 23 Pinto H C, Baptista A, Camilo M E, Valente A, Saragoca A, de Moura M C. Nonalcoholic steatohepatitis: clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients.  Dig Dis Sci. 1996;  41(1) 172-179
    PubMedGoogle Scholar
  • 24 Gramlich T, Kleiner D E, McCullough A J, Matteoni C A, Boparai N, Younossi Z M. Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.  Hum Pathol. 2004;  35(2) 196-199
    CrossrefPubMedGoogle Scholar
  • 25 Leclercq I A, Horsmans Y. Cell biology of NASH: fibrosis and cell proliferation. In: Farrell GC, George J, Hall P de la M, McCullough AK Fatty Liver Disease: NASH and Related Disorders. Oxford; Blackwell 2005: 143-158
    Google Scholar
  • 26 Powell E E, Cooksley W G, Hanson R, Searle J, Halliday J W, Powell L W. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years.  Hepatology. 1990;  11(1) 74-80
    CrossrefPubMedGoogle Scholar
  • 27 Teli M R, James O F, Burt A D, Bennett M K, Day C P. The natural history of nonalcoholic fatty liver: a follow-up study.  Hepatology. 1995;  22(6) 1714-1719
    CrossrefPubMedGoogle Scholar
  • 28 Matteoni C A, Younossi Z M, Gramlich T, Boparai N, Liu Y C, McCullough A J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.  Gastroenterology. 1999;  116(6) 1413-1419
    CrossrefPubMedGoogle Scholar
  • 29 Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies.  Hepatology. 2004;  40(4) 820-826
    PubMedGoogle Scholar
  • 30 Adams L A, Sanderson S, Lindor K D, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies.  J Hepatol. 2005;  42(1) 132-138
    CrossrefPubMedGoogle Scholar
  • 31 Adams L A, Lymp J F, St Sauver J et al.. The natural history of nonalcoholic fatty liver disease: a population-based cohort study.  Gastroenterology. 2005;  129(1) 113-121
    CrossrefPubMedGoogle Scholar
  • 32 Gholam P M, Flancbaum L, Machan J T, Charney D A, Kotler D P. Nonalcoholic fatty liver disease in severely obese subjects.  Am J Gastroenterol. 2007;  102(2) 399-408
    CrossrefPubMedGoogle Scholar
  • 33 Clark J M, Diehl A M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis.  JAMA. 2003;  289(22) 3000-3004
    CrossrefPubMedGoogle Scholar
  • 34 Caldwell S H, Crespo D M. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.  J Hepatol. 2004;  40(4) 578-584
    CrossrefPubMedGoogle Scholar
  • 35 Caldwell S HHA. The clinical outcome of NAFLD including cryptogenic cirrhosis. In: Farrell GC, George J, Hall P de la M, McCullough AK Fatty Liver Disease: NASH and Related Disorders. Oxford; Blackwell 2005: 168-180
    Google Scholar
  • 36 Farrell G C, Larter C Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.  Hepatology. 2006;  43(suppl 1) S99-S112
    CrossrefPubMedGoogle Scholar
  • 37 Charlton M, Kasparova P, Weston S et al.. Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.  Liver Transpl. 2001;  7(7) 608-614
    CrossrefPubMedGoogle Scholar
  • 38 Burke A, Lucey M R. Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and orthotopic liver transplantation.  Am J Transplant. 2004;  4(5) 686-693
    CrossrefPubMedGoogle Scholar
  • 39 Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact.  Clin Gastroenterol Hepatol. 2004;  2(12) 1048-1058
    CrossrefPubMedGoogle Scholar
  • 40 Bugianesi E, Marzocchi R, Villanova N, Marchesini G. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment.  Best Pract Res Clin Gastroenterol. 2004;  18(6) 1105-1116
    PubMedGoogle Scholar
  • 41 Rafiq N, Younossi Z M. Effects of weight loss on nonalcoholic fatty liver disease.  Semin Liver Dis. 2008;  28 427-433
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Belfort R, Harrison S A, Brown K et al.. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis.  N Engl J Med. 2006;  355(22) 2297-2307
    CrossrefPubMedGoogle Scholar
  • 43 Ghali P, Lindor K D. Hepatotoxicity of drugs used for treatment of obesity and its comorbidities.  Semin Liver Dis. 2004;  24(4) 389-397
    Article in Thieme ConnectPubMedGoogle Scholar
  • 44 Neuschwander-Tetri B A. Nonalcoholic steatohepatitis and the metabolic syndrome.  Am J Med Sci. 2005;  330(6) 326-335
    CrossrefPubMedGoogle Scholar
  • 45 Grattagliano I, Portincasa P, Palmieri V O, Palasciano G. Managing nonalcoholic fatty liver disease: recommendations for family physicians.  Can Fam Physician. 2007;  53(5) 857-863
    PubMedGoogle Scholar
  • 46 Kadayifci A, Merriman R B, Bass N M. Medical treatment of non-alcoholic steatohepatitis.  Clin Liver Dis. 2007;  11(1) 119-140 ix
    CrossrefPubMedGoogle Scholar
  • 47 Clark J M. Weight loss as a treatment for nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40(suppl 1) S39-S43
    PubMedGoogle Scholar
  • 48 Stremmel W, Berk P D. Hepatocellular influx of [14C]oleate reflects membrane transport rather than intracellular metabolism or binding.  Proc Natl Acad Sci U S A. 1986;  83(10) 3086-3090
    CrossrefPubMedGoogle Scholar
  • 49 Schwieterman W, Sorrentino D, Potter B J et al.. Uptake of oleate by isolated rat adipocytes is mediated by a 40-kDa plasma membrane fatty acid binding protein closely related to that in liver and gut.  Proc Natl Acad Sci U S A. 1988;  85(2) 359-363
    CrossrefPubMedGoogle Scholar
  • 50 Sorrentino D, Stump D, Potter B J et al.. Oleate uptake by cardiac myocytes is carrier mediated and involves a 40-kD plasma membrane fatty acid binding protein similar to that in liver, adipose tissue, and gut.  J Clin Invest. 1988;  82(3) 928-935
    CrossrefPubMedGoogle Scholar
  • 51 Stremmel W. Uptake of fatty acids by jejunal mucosal cells is mediated by a fatty acid binding membrane protein.  J Clin Invest. 1988;  82(6) 2001-2010
    CrossrefPubMedGoogle Scholar
  • 52 Nunes R M, Isola L M, Sorrentino D, Berk P D. Oleate uptake by isolated hepatocytes consists of two components, each driven by the unbound oleate concentration. In: Proceedings of the 3rd International Congress, Mathematical Modelling of Liver Excretory Process Tokyo; Juntendo University Press 1990: 312-316
    Google Scholar
  • 53 Stump D D, Nunes R M, Sorrentino D, Isola L M, Berk P D. Characteristics of oleate binding to liver plasma membranes and its uptake by isolated hepatocytes.  J Hepatol. 1992;  16(3) 304-315
    CrossrefPubMedGoogle Scholar
  • 54 Berk P D, Stump D D. Mechanisms of cellular uptake of long chain free fatty acids.  Mol Cell Biochem. 1999;  192(1–2) 17-31
    CrossrefPubMedGoogle Scholar
  • 55 Stump D D, Fan X, Berk P D. Oleic acid uptake and binding by rat adipocytes define dual pathways for cellular fatty acid uptake.  J Lipid Res. 2001;  42(4) 509-520
    PubMedGoogle Scholar
  • 56 Stoll G H, Voges R, Gerok W, Kurz G. Synthesis of a metabolically stable modified long-chain fatty acid salt and its photolabile derivative.  J Lipid Res. 1991;  32(5) 843-857
    PubMedGoogle Scholar
  • 57 Schmider W, Fahr A, Blum H E, Kurz G. Transport of heptafluorostearate across model membranes: membrane transport of long-chain fatty acid anions I.  J Lipid Res. 2000;  41(5) 775-787
    PubMedGoogle Scholar
  • 58 Abumrad N A, Perkins R C, Park J H, Park C R. Mechanism of long chain fatty acid permeation in the isolated adipocyte.  J Biol Chem. 1981;  256(17) 9183-9191
    PubMedGoogle Scholar
  • 59 Abumrad N A, Park J H, Park C R. Permeation of long-chain fatty acid into adipocytes: kinetics, specificity, and evidence for involvement of a membrane protein.  J Biol Chem. 1984;  259(14) 8945-8953
    PubMedGoogle Scholar
  • 60 Weisiger R A, Fitz J G, Scharschmidt B F. Hepatic oleate uptake: electrochemical driving forces in intact rat liver.  J Clin Invest. 1989;  83(2) 411-420
    CrossrefPubMedGoogle Scholar
  • 61 Glatz J F, van Nieuwenhoven F A, Luiken J J, Schaap F G, van der Vusse G J. Role of membrane-associated and cytoplasmic fatty acid-binding proteins in cellular fatty acid metabolism.  Prostaglandins Leukot Essent Fatty Acids. 1997;  57(4–5) 373-378
    CrossrefPubMedGoogle Scholar
  • 62 Luiken J J, Turcotte L P, Bonen A. Protein-mediated palmitate uptake and expression of fatty acid transport proteins in heart giant vesicles.  J Lipid Res. 1999;  40(6) 1007-1016
    PubMedGoogle Scholar
  • 63 Luiken J J, Glatz J F, Bonen A. Fatty acid transport proteins facilitate fatty acid uptake in skeletal muscle.  Can J Appl Physiol. 2000;  25(5) 333-352
    PubMedGoogle Scholar
  • 64 Kampf J P, Kleinfeld A M. Fatty acid transport in adipocytes monitored by imaging intracellular free fatty acid levels.  J Biol Chem. 2004;  279(34) 35775-35780
    CrossrefPubMedGoogle Scholar
  • 65 Kleinfeld A M, Kampf J P, Lechene C. Transport of 13C-oleate in adipocytes measured using multi imaging mass spectrometry.  J Am Soc Mass Spectrom. 2004;  15(11) 1572-1580
    CrossrefPubMedGoogle Scholar
  • 66 Stremmel W, Strohmeyer G, Borchard F, Kochwa S, Berk P D. Isolation and partial characterization of a fatty acid binding protein in rat liver plasma membranes.  Proc Natl Acad Sci U S A. 1985;  82(1) 4-8
    CrossrefPubMedGoogle Scholar
  • 67 Bradbury M W, Berk P D. Cellular uptake of long chain free fatty acids: the structure and function of plasma membrane fatty acid binding protein.  Adv Mol Cell Biol. 2004;  33 47-81
    PubMedGoogle Scholar
  • 68 Berk P D, Wada H, Horio Y et al.. Plasma membrane fatty acid-binding protein and mitochondrial glutamic-oxaloacetic transaminase of rat liver are related.  Proc Natl Acad Sci U S A. 1990;  87(9) 3484-3488
    CrossrefPubMedGoogle Scholar
  • 69 Stump D D, Zhou S L, Berk P D. Comparison of plasma membrane FABP and mitochondrial isoform of aspartate aminotransferase from rat liver.  Am J Physiol. 1993;  265(5 Pt 1) G894-G902
    PubMedGoogle Scholar
  • 70 Abumrad N A, el-Maghrabi M R, Amri E Z, Lopez E, Grimaldi P A. Cloning of a rat adipocyte membrane protein implicated in binding or transport of long-chain fatty acids that is induced during preadipocyte differentiation: homology with human CD36.  J Biol Chem. 1993;  268(24) 17665-17668
    PubMedGoogle Scholar
  • 71 Schaffer J E, Lodish H F. Expression cloning and characterization of a novel adipocyte long chain fatty acid transport protein.  Cell. 1994;  79(3) 427-436
    CrossrefPubMedGoogle Scholar
  • 72 Hirsch D, Stahl A, Lodish H F. A family of fatty acid transporters conserved from mycobacterium to man.  Proc Natl Acad Sci U S A. 1998;  95(15) 8625-8629
    CrossrefPubMedGoogle Scholar
  • 73 Stahl A, Gimeno R E, Tartaglia L A, Lodish H F. Fatty acid transport proteins: a current view of a growing family.  Trends Endocrinol Metab. 2001;  12(6) 266-273
    PubMedGoogle Scholar
  • 74 Trigatti B L, Anderson R G, Gerber G E. Identification of caveolin-1 as a fatty acid binding protein.  Biochem Biophys Res Commun. 1999;  255(1) 34-39
    CrossrefPubMedGoogle Scholar
  • 75 Pohl J, Ring A, Stremmel W. Uptake of long-chain fatty acids in HepG2 cells involves caveolae: analysis of a novel pathway.  J Lipid Res. 2002;  43(9) 1390-1399
    CrossrefPubMedGoogle Scholar
  • 76 Kampf J P, Parmley D, Kleinfeld A M. Free fatty acid transport across adipocytes is mediated by an unknown membrane protein pump.  Am J Physiol Endocrinol Metab. 2007;  293(5) E1207-E1214
    CrossrefPubMedGoogle Scholar
  • 77 Berk P D, Zhou S L, Kiang C L, Stump D, Bradbury M, Isola L M. Uptake of long chain free fatty acids is selectively up-regulated in adipocytes of Zucker rats with genetic obesity and non-insulin-dependent diabetes mellitus.  J Biol Chem. 1997;  272(13) 8830-8835
    CrossrefPubMedGoogle Scholar
  • 78 Berk P D, Zhou S L, Bradbury M, Stump D, Kiang C L, Isola L M. Regulated membrane transport of free fatty acids in adipocytes: role in obesity and non-insulin dependent diabetes mellitus.  Trans Am Clin Climatol Assoc. 1997;  108 26-40 , discussion 41–43
    PubMedGoogle Scholar
  • 79 Berk P D, Zhou S, Kiang C, Stump D D, Fan X, Bradbury M W. Selective up-regulation of fatty acid uptake by adipocytes characterizes both genetic and diet-induced obesity in rodents.  J Biol Chem. 1999;  274(40) 28626-28631
    CrossrefPubMedGoogle Scholar
  • 80 Petrescu O, Fan X, Gentileschi P et al.. Long-chain fatty acid uptake is upregulated in omental adipocytes from patients undergoing bariatric surgery for obesity.  Int J Obes (Lond). 2005;  29(2) 196-203
    CrossrefPubMedGoogle Scholar
  • 81 Bradbury M W, Berk P D. Lipid metabolism in hepatic steatosis.  Clin Liver Dis. 2004;  8(3) 639-671 xi
    CrossrefPubMedGoogle Scholar
  • 82 Lee G H, Proenca R, Montez J M et al.. Abnormal splicing of the leptin receptor in diabetic mice.  Nature. 1996;  379(6566) 632-635
    CrossrefPubMedGoogle Scholar
  • 83 Chua Jr S C, Chung W K, Wu-Peng X S et al.. Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor.  Science. 1996;  271(5251) 994-996
    PubMedGoogle Scholar
  • 84 Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman J M. Positional cloning of the mouse obese gene and its human homologue.  Nature. 1994;  372(6505) 425-432
    CrossrefPubMedGoogle Scholar
  • 85 Fan X, Bradbury M W, Berk P D. Leptin and insulin modulate nutrient partitioning and weight loss in ob/ob mice through regulation of long-chain fatty acid uptake by adipocytes.  J Nutr. 2003;  133(9) 2707-2715
    PubMedGoogle Scholar
  • 86 Lee Y, Wang M Y, Kakuma T et al.. Liporegulation in diet-induced obesity: the antisteatotic role of hyperleptinemia.  J Biol Chem. 2001;  276(8) 5629-5635
    CrossrefPubMedGoogle Scholar
  • 87 Unger R H. Lipotoxic diseases.  Annu Rev Med. 2002;  53 319-336
    CrossrefPubMedGoogle Scholar
  • 88 Unger R H. The physiology of cellular liporegulation.  Annu Rev Physiol. 2003;  65 333-347
    CrossrefPubMedGoogle Scholar
  • 89 Halaas J L, Gajiwala K S, Maffei M et al.. Weight-reducing effects of the plasma protein encoded by the obese gene.  Science. 1995;  269(5223) 543-546
    CrossrefPubMedGoogle Scholar
  • 90 Pelleymounter M A, Cullen M J, Baker M B et al.. Effects of the obese gene product on body weight regulation in ob/ob mice.  Science. 1995;  269(5223) 540-543
    CrossrefPubMedGoogle Scholar
  • 91 Campfield L A, Smith F J, Guisez Y, Devos R, Burn P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks.  Science. 1995;  269(5223) 546-549
    CrossrefPubMedGoogle Scholar
  • 92 Remesar X, Rafecas I, Fernandez-Lopez J A, Alemany M. Is leptin an insulin counter-regulatory hormone?.  FEBS Lett. 1997;  402(1) 9-11
    CrossrefPubMedGoogle Scholar
  • 93 Myers M G, Cowley M A, Munzberg H. Mechanisms of leptin action and leptin resistance.  Annu Rev Physiol. 2008;  70 537-556
    CrossrefPubMedGoogle Scholar
  • 94 Oh-I S, Shimizu H, Sato T, Uehara Y, Okada S, Mori M. Molecular mechanisms associated with leptin resistance: n-3 polyunsaturated fatty acids induce alterations in the tight junction of the brain.  Cell Metab. 2005;  1(5) 331-341
    CrossrefPubMedGoogle Scholar
  • 95 Listenberger L L, Ory D S, Schaffer J E. Palmitate-induced apoptosis can occur through a ceramide-independent pathway.  J Biol Chem. 2001;  276(18) 14890-14895
    CrossrefPubMedGoogle Scholar
  • 96 Unger R H, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders.  FASEB J. 2001;  15(2) 312-321
    CrossrefPubMedGoogle Scholar
  • 97 Unger R H. Minireview: weapons of lean body mass destruction—the role of ectopic lipids in the metabolic syndrome.  Endocrinology. 2003;  144(12) 5159-5165
    CrossrefPubMedGoogle Scholar
  • 98 Schaffer J E. Lipotoxicity: when tissues overeat.  Curr Opin Lipidol. 2003;  14(3) 281-287
    CrossrefPubMedGoogle Scholar
  • 99 Shimomura I, Hammer R E, Ikemoto S, Brown M S, Goldstein J L. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy.  Nature. 1999;  401(6748) 73-76
    CrossrefPubMedGoogle Scholar
  • 100 Bray G A. Medical consequences of obesity.  J Clin Endocrinol Metab. 2004;  89(6) 2583-2589
    CrossrefPubMedGoogle Scholar
  • 101 Reaven G M. Role of insulin resistance in human disease (syndrome X): an expanded definition.  Annu Rev Med. 1993;  44 121-131
    CrossrefPubMedGoogle Scholar
  • 102 Reaven G M. Pathophysiology of insulin resistance in human disease.  Physiol Rev. 1995;  75(3) 473-486
    PubMedGoogle Scholar
  • 103 Dunbar R L, Rader D J. Slaying the metabolic syndrome: are we battling the Hydra or the Chimera?.  Minerva Endocrinol. 2004;  29(3) 89-111
    PubMedGoogle Scholar
  • 104 Reaven G. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease.  Circulation. 2002;  106(3) 286-288
    CrossrefPubMedGoogle Scholar
  • 105 Freedland E S. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review.  Nutr Metab (Lond). 2004;  1(1) 12
    CrossrefPubMedGoogle Scholar
  • 106 Haynes P, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease in individuals with severe obesity.  Clin Liver Dis. 2004;  8(3) 535-547
    CrossrefPubMedGoogle Scholar
  • 107 Choudhury J, Sanyal A J. Insulin resistance and the pathogenesis of nonalcoholic fatty liver disease.  Clin Liver Dis. 2004;  8(3) 575-594 ix
    PubMedGoogle Scholar
  • 108 Marceau P, Biron S, Hould F S et al.. Liver pathology and the metabolic syndrome X in severe obesity.  J Clin Endocrinol Metab. 1999;  84(5) 1513-1517
    CrossrefPubMedGoogle Scholar
  • 109 Pagano G, Pacini G, Musso G et al.. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association.  Hepatology. 2002;  35(2) 367-372
    CrossrefPubMedGoogle Scholar
  • 110 Wisse B E. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity.  J Am Soc Nephrol. 2004;  15(11) 2792-2800
    CrossrefPubMedGoogle Scholar
  • 111 Kerner A, Avizohar O, Sella R et al.. Association between elevated liver enzymes and C-reactive protein: possible hepatic contribution to systemic inflammation in the metabolic syndrome.  Arterioscler Thromb Vasc Biol. 2005;  25(1) 193-197
    PubMedGoogle Scholar
  • 112 Ferroni P, Basili S, Falco A, Davi G. Inflammation, insulin resistance, and obesity.  Curr Atheroscler Rep. 2004;  6(6) 424-431
    CrossrefPubMedGoogle Scholar
  • 113 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.  Circulation. 2002;  106(25) 3143-3421
    PubMedGoogle Scholar
  • 114 Grundy S M, Hansen B, Smith Jr S C, Cleeman J I, Kahn R A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management.  Arterioscler Thromb Vasc Biol. 2004;  24(2) e19-e24
    PubMedGoogle Scholar
  • 115 Grundy S M, Brewer Jr H B, Cleeman J I, Smith Jr S C, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.  Arterioscler Thromb Vasc Biol. 2004;  24(2) e13-e18
    CrossrefPubMedGoogle Scholar
  • 116 Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2005;  28(9) 2289-2304
    CrossrefPubMedGoogle Scholar
  • 117 Reaven G M. The individual components of the metabolic syndrome: is there a raison d'etre?.  J Am Coll Nutr. 2007;  26(3) 191-195
    PubMedGoogle Scholar
  • 118 Chirieac D V, Chirieac L R, Corsetti J P, Cianci J, Sparks C E, Sparks J D. Glucose-stimulated insulin secretion suppresses hepatic triglyceride-rich lipoprotein and apoB production.  Am J Physiol Endocrinol Metab. 2000;  279(5) E1003-E1011
    PubMedGoogle Scholar
  • 119 Diehl A M. Lessons from animal models of NASH.  Hepatol Res. 2005;  33(2) 138-144
    CrossrefPubMedGoogle Scholar
  • 120 Yamaguchi K, Yang L, McCall S et al.. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.  Hepatology. 2007;  45(6) 1366-1374
    CrossrefPubMedGoogle Scholar
  • 121 Zhou S L, Gordon R E, Bradbury M, Stump D, Kiang C L, Berk P D. Ethanol up-regulates fatty acid uptake and plasma membrane expression and export of mitochondrial aspartate aminotransferase in HepG2 cells.  Hepatology. 1998;  27(4) 1064-1074
    CrossrefPubMedGoogle Scholar
  • 122 Berk P D, Zhou S, Bradbury M W. Increased hepatocellular uptake of long chain fatty acids occurs by different mechanisms in fatty livers due to obesity or excess ethanol use, contributing to development of steatohepatitis in both settings.  Trans Am Clin Climatol Assoc. 2005;  116 335-344 , discussion 345
    PubMedGoogle Scholar
  • 123 Day C P, James O F. Steatohepatitis: a tale of two “hits”?.  Gastroenterology. 1998;  114(4) 842-845
    CrossrefPubMedGoogle Scholar
  • 124 McCullough A J. Pathophysiology of nonalcoholic steatohepatitis.  J Clin Gastroenterol. 2006;  40(suppl 1) S17-S29
    PubMedGoogle Scholar
  • 125 Merriman R B, Aouizerat B E, Bass N M. Genetic influences in nonalcoholic fatty liver disease.  J Clin Gastroenterol. 2006;  40(suppl 1) S30-S33
    PubMedGoogle Scholar
  • 126 Mantena S K, King A L, Andringa K K, Eccleston H B, Bailey S M. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases.  Free Radic Biol Med. 2008;  44(7) 1259-1272
    CrossrefPubMedGoogle Scholar
  • 127 Malhi H, Gores G J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease.  Semin Liver Dis. 2008;  28 360-369
    Article in Thieme ConnectPubMedGoogle Scholar
  • 128 Jou J, Choi S S, Diehl A M. Mechanisms of disease progression in nonalcoholic fatty liver disease.  Semin Liver Dis. 2008;  28 370-379
    Article in Thieme ConnectPubMedGoogle Scholar
  • 129 Charlton M. Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon.  Am J Gastroenterol. 2007;  102(2) 409-411
    CrossrefPubMedGoogle Scholar
  • 130 Leclercq I A, Farrell G C, Field J, Bell D R, Gonzalez F J, Robertson G R. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis.  J Clin Invest. 2000;  105(8) 1067-1075
    PubMedGoogle Scholar
  • 131 Robertson G, Leclercq I, Farrell G C. Nonalcoholic steatosis and steatohepatitis: II. Cytochrome P-450 enzymes and oxidative stress.  Am J Physiol Gastrointest Liver Physiol. 2001;  281(5) G1135-G1139
    PubMedGoogle Scholar
  • 132 Sanyal A J, Campbell-Sargent C, Mirshahi F et al.. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities.  Gastroenterology. 2001;  120(5) 1183-1192
    CrossrefPubMedGoogle Scholar
  • 133 Chitturi S, Abeygunasekera S, Farrell G C et al.. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome.  Hepatology. 2002;  35(2) 373-379
    CrossrefPubMedGoogle Scholar
  • 134 Chitturi S, Farrell G, Frost L et al.. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?.  Hepatology. 2002;  36(2) 403-409
    CrossrefPubMedGoogle Scholar
  • 135 Hui J M, Hodge A, Farrell G C, Kench J G, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin?.  Hepatology. 2004;  40(1) 46-54
    CrossrefPubMedGoogle Scholar
  • 136 Puri P, Baillie R A, Wiest M M et al.. A lipidomic analysis of nonalcoholic fatty liver disease.  Hepatology. 2007;  46(4) 1081-1090
    CrossrefPubMedGoogle Scholar
  • 137 Puri P, Mirshahi F, Cheung O et al.. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease.  Gastroenterology. 2008;  134(2) 568-576
    CrossrefPubMedGoogle Scholar
  • 138 Bray G A. Drug treatment of obesity.  Rev Endocr Metab Disord. 2001;  2(4) 403-418
    CrossrefPubMedGoogle Scholar
  • 139 Klein S, Wadden T, Sugerman H J. AGA technical review on obesity.  Gastroenterology. 2002;  123(3) 882-932
    CrossrefPubMedGoogle Scholar
  • 140 Anderson J W, Konz E C, Frederich R C, Wood C L. Long-term weight-loss maintenance: a meta-analysis of US studies.  Am J Clin Nutr. 2001;  74(5) 579-584
    PubMedGoogle Scholar
  • 141 Wadden T A, Foster G D. Behavioral treatment of obesity.  Med Clin North Am. 2000;  84(2) 441-461 vii
    CrossrefPubMedGoogle Scholar
  • 142 National Institutes of Health . Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: The Evidence Report.  Obes Res. 1998;  6(suppl 2) 51S-209S
    PubMedGoogle Scholar
  • 143 Leibel R L, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight.  N Engl J Med. 1995;  332(10) 621-628
    CrossrefPubMedGoogle Scholar
  • 144 Weinsier R L, Nagy T R, Hunter G R, Darnell B E, Hensrud D D, Weiss H L. Do adaptive changes in metabolic rate favor weight regain in weight-reduced individuals? An examination of the set-point theory.  Am J Clin Nutr. 2000;  72(5) 1088-1094
    PubMedGoogle Scholar
  • 145 Mason E E, Ito C. Gastric bypass in obesity.  Surg Clin North Am. 1967;  47(6) 1345-1351
    PubMedGoogle Scholar
  • 146 Hubbard V S, Hall W H. Gastrointestinal surgery for severe obesity.  Obes Surg. 1991;  1(3) 257-265
    CrossrefPubMedGoogle Scholar
  • 147 Zhao Y, Encinosa W. Agency for Healthcare Research and Quality (AHRQ), Bariatric Surgery Utilization and Outcomes in 1998 and 2004. Statistical Brief # 23. Rockville, MD; Agency or Healthcare Quality and Research 2007
    Google Scholar
  • 148 NIDDK Working group on bariatric surgery: executive summary (2002). American Society for Bariatric Surgery. Rationale for the surgical treatment of morbid obesity. Available at: http://www.asbs.org/html/rationale/rationale.html Accessed April 14, 2008
    Google Scholar
  • 149 Brolin R E. Gastric bypass.  Surg Clin North Am. 2001;  81(5) 1077-1095
    CrossrefPubMedGoogle Scholar
  • 150 Pories W J, Swanson M S, MacDonald K G et al.. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus.  Ann Surg. 1995;  222(3) 339-350 , discussion 350–352
    CrossrefPubMedGoogle Scholar
  • 151 Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus.  Ann Surg. 2002;  236(5) 554-559
    CrossrefPubMedGoogle Scholar
  • 152 Kral J G, Naslund E. Surgical treatment of obesity.  Nat Clin Pract Endocrinol Metab. 2007;  3(8) 574-583
    CrossrefPubMedGoogle Scholar
  • 153 Elder K A, Wolfe B M. Bariatric surgery: a review of procedures and outcomes.  Gastroenterology. 2007;  132(6) 2253-2271
    CrossrefPubMedGoogle Scholar
  • 154 Buchwald H. A bariatric surgery algorithm.  Obes Surg. 2002;  12(6) 733-746 , discussion 747–750
    CrossrefPubMedGoogle Scholar
  • 155 Regan J, Selzer D J, Inabnet W B. Choosing the right laparoscopic bariatric surgical procedure. In: Inabnet WB, DeMaria EJ, Ikramuddin S Laparoscopic Bariatric Surgery. Philadelphia; Lippincott Williams and Wilkins 2004: 47-54
    Google Scholar
  • 156 Belle S H, Berk P D, Courcoulas A P et al.. Safety and efficacy of bariatric surgery: longitudinal assessment of bariatric surgery.  Surg Obes Relat Dis. 2007;  3(2) 116-126
    CrossrefPubMedGoogle Scholar
  • 157 DeMaria E J, Jamal M K. Laparoscopic adjustable gastric banding: evolving clinical experience.  Surg Clin North Am. 2005;  85(4) 773-787 vii
    CrossrefPubMedGoogle Scholar
  • 158 Gagner M, Inabnet W B, Pomp A. Laparoscopic sleeve gastrectomy with second stage biliopancreatic diversion and duodenal switch in the superobese. In: Inabnet WB, DeMaria EJ, Ikramuddin S Laparoscopic Bariatric Surgery. Philadelphia; Lippincott Williams and Wilkins 2004: 143-150
    Google Scholar
  • 159 Scharf M T, Ahima R S. Gut peptides and other regulators in obesity.  Semin Liver Dis. 2004;  24(4) 335-347
    Article in Thieme ConnectPubMedGoogle Scholar
  • 160 Murphy K G, Dhillo W S, Bloom S R. Gut peptides in the regulation of food intake and energy homeostasis.  Endocr Rev. 2006;  27(7) 719-727
    CrossrefPubMedGoogle Scholar
  • 161 Wren A M, Bloom S R. Gut hormones and appetite control.  Gastroenterology. 2007;  132(6) 2116-2130
    CrossrefPubMedGoogle Scholar
  • 162 Chaudhri O B, Salem V, Murphy K G, Bloom S R. Gastrointestinal satiety signals.  Annu Rev Physiol. 2008;  70 239-255
    CrossrefPubMedGoogle Scholar
  • 163 de Fatima Haueisen Sander Diniz M, de Azeredo Passos V M, Diniz M T. Gut-brain communication: how does it stand after bariatric surgery?.  Curr Opin Clin Nutr Metab Care. 2006;  9(5) 629-636
    PubMedGoogle Scholar
  • 164 le Roux C W, Aylwin S J, Batterham R L et al.. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters.  Ann Surg. 2006;  243(1) 108-114
    CrossrefPubMedGoogle Scholar
  • 165 le Roux C W, Welbourn R, Werling M et al.. Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass.  Ann Surg. 2007;  246(5) 780-785
    CrossrefPubMedGoogle Scholar
  • 166 Wren A M, Seal L J, Cohen M A et al.. Ghrelin enhances appetite and increases food intake in humans.  J Clin Endocrinol Metab. 2001;  86(12) 5992
    CrossrefPubMedGoogle Scholar
  • 167 Cummings D E, Weigle D S, Frayo R S et al.. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery.  N Engl J Med. 2002;  346(21) 1623-1630
    CrossrefPubMedGoogle Scholar
  • 168 Nakazato M, Murakami N, Date Y et al.. A role for ghrelin in the central regulation of feeding.  Nature. 2001;  409(6817) 194-198
    CrossrefPubMedGoogle Scholar
  • 169 Korner J, Inabnet W, Conwell I M et al.. Differential effects of gastric bypass and banding on circulating gut hormone and leptin levels.  Obesity (Silver Spring). 2006;  14(9) 1553-1561
    CrossrefPubMedGoogle Scholar
  • 170 Foschi D, Corsi F, Colombo F et al.. Different effects of vertical banded gastroplasty and Roux-en-Y gastric bypass on meal inhibition of ghrelin secretion in morbidly obese patients.  J Invest Surg. 2008;  21(2) 77-81
    CrossrefPubMedGoogle Scholar
  • 171 Kotidis E V, Koliakos G G, Baltzopoulos V G, Ioannidis K N, Yovos J G, Papavramidis S T. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment—a prospective study.  Obes Surg. 2006;  16(11) 1425-1432
    CrossrefPubMedGoogle Scholar
  • 172 Chan J L, Mun E C, Stoyneva V, Mantzoros C S, Goldfine A B. Peptide YY levels are elevated after gastric bypass surgery.  Obesity (Silver Spring). 2006;  14(2) 194-198
    CrossrefPubMedGoogle Scholar
  • 173 Brolin R E, Bradley L J, Taliwal R V. Unsuspected cirrhosis discovered during elective obesity operations.  Arch Surg. 1998;  133(1) 84-88
    CrossrefPubMedGoogle Scholar
  • 174 Drenick E J, Simmons F, Murphy J F. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small-bowel bypass.  N Engl J Med. 1970;  282(15) 829-834
    CrossrefPubMedGoogle Scholar
  • 175 Marubbio Jr A T, Buchwald H, Schwartz M Z, Varco R. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass.  Am J Clin Pathol. 1976;  66(4) 684-691
    PubMedGoogle Scholar
  • 176 Campbell J M, Hunt T K, Karam J H, Forsham P H. Jejunoileal bypass as a treatment of morbid obesity.  Arch Intern Med. 1977;  137(5) 602-610
    CrossrefPubMedGoogle Scholar
  • 177 Vyberg M, Ravn V, Andersen B. Pattern of progression in liver injury following jejunoileal bypass for morbid obesity.  Liver. 1987;  7(5) 271-276
    PubMedGoogle Scholar
  • 178 Hocking M P, Duerson M C, O'Leary J P, Woodward E R. Jejunoileal bypass for morbid obesity: late follow-up in 100 cases.  N Engl J Med. 1983;  308(17) 995-999
    CrossrefPubMedGoogle Scholar
  • 179 Marubbio A T, Rucker Jr R D, Schneider P D, Horstmann J P, Varco R L, Buchwald H. The liver in morbid obesity and following bypass surgery for obesity.  Surg Clin North Am. 1979;  59(6) 1079-1093
    PubMedGoogle Scholar
  • 180 DeWind L T, Payne J H. Intestinal bypass surgery for morbid obesity: long-term results.  JAMA. 1976;  236(20) 2298-2301
    CrossrefPubMedGoogle Scholar
  • 181 Andersen T, Gluud C, Franzmann M B, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects.  J Hepatol. 1991;  12(2) 224-229
    CrossrefPubMedGoogle Scholar
  • 182 Drenick E J, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass: prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition.  Gastroenterology. 1982;  82(3) 535-548
    CrossrefPubMedGoogle Scholar
  • 183 Siegmund S V, Dooley S, Brenner D A. Molecular mechanisms of alcohol-induced hepatic fibrosis.  Dig Dis. 2005;  23(3–4) 264-274
    CrossrefPubMedGoogle Scholar
  • 184 Ruiz A G, Casafont F, Crespo J et al.. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis.  Obes Surg. 2007;  17(10) 1374-1380
    CrossrefPubMedGoogle Scholar
  • 185 Meinhardt N G, Souto K E, Ulbrich-Kulczynski J M, Stein A T. Hepatic outcomes after jejunoileal bypass: is there a publication bias?.  Obes Surg. 2006;  16(9) 1171-1178
    CrossrefPubMedGoogle Scholar
  • 186 Wills C E. Long-term follow-up of jejunoileal bypass patients with preoperative cirrhosis of the liver.  Obes Surg. 1994;  4(1) 37-39
    CrossrefPubMedGoogle Scholar
  • 187 Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity.  Digestion. 1990;  47(4) 208-214
    PubMedGoogle Scholar
  • 188 Grimm I S, Schindler W, Haluszka O. Steatohepatitis and fatal hepatic failure after biliopancreatic diversion.  Am J Gastroenterol. 1992;  87(6) 775-779
    PubMedGoogle Scholar
  • 189 Silverman E M, Sapala J A, Appelman H D. Regression of hepatic steatosis in morbidly obese persons after gastric bypass.  Am J Clin Pathol. 1995;  104(1) 23-31
    PubMedGoogle Scholar
  • 190 Dixon J B, Bhathal P S, Hughes N R, O'Brien P E. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss.  Hepatology. 2004;  39(6) 1647-1654
    CrossrefPubMedGoogle Scholar
  • 191 Luyckx F H, Desaive C, Thiry A et al.. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty.  Int J Obes Relat Metab Disord. 1998;  22(3) 222-226
    CrossrefPubMedGoogle Scholar
  • 192 Kral J G, Thung S N, Biron S et al.. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis.  Surgery. 2004;  135(1) 48-58
    CrossrefPubMedGoogle Scholar
  • 193 Clark J M, Alkhuraishi A R, Solga S F, Alli P, Diehl A M, Magnuson T H. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease.  Obes Res. 2005;  13(7) 1180-1186
    CrossrefPubMedGoogle Scholar
  • 194 Stratopoulos C, Papakonstantinou A, Terzis I et al.. Changes in liver histology accompanying massive weight loss after gastroplasty for morbid obesity.  Obes Surg. 2005;  15(8) 1154-1160
    CrossrefPubMedGoogle Scholar
  • 195 Mattar S G, Velcu L M, Rabinovitz M et al.. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome.  Ann Surg. 2005;  242(4) 610-617 , discussion 618–620
    PubMedGoogle Scholar
  • 196 Mottin C C, Moretto M, Padoin A V et al.. Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery.  Obes Surg. 2005;  15(6) 788-793
    CrossrefPubMedGoogle Scholar
  • 197 de Almeida S R, Rocha P R, Sanches M D et al.. Roux-en-Y gastric bypass improves the nonalcoholic steatohepatitis (NASH) of morbid obesity.  Obes Surg. 2006;  16(3) 270-278
    CrossrefPubMedGoogle Scholar
  • 198 Klein S, Mittendorfer B, Eagon J C et al.. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease.  Gastroenterology. 2006;  130(6) 1564-1572
    CrossrefPubMedGoogle Scholar
  • 199 Jaskiewicz K, Raczynska S, Rzepko R, Sledzinski Z. Nonalcoholic fatty liver disease treated by gastroplasty.  Dig Dis Sci. 2006;  51(1) 21-26
    CrossrefPubMedGoogle Scholar
  • 200 Barker K B, Palekar N A, Bowers S P, Goldberg J E, Pulcini J P, Harrison S A. Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery.  Am J Gastroenterol. 2006;  101(2) 368-373
    CrossrefPubMedGoogle Scholar
  • 201 Mathurin P, Gonzalez F, Kerdraon O et al.. The evolution of severe steatosis after bariatric surgery is related to insulin resistance.  Gastroenterology. 2006;  130(6) 1617-1624
    CrossrefPubMedGoogle Scholar
  • 202 Csendes A, Smok G, Burgos A M. Histological findings in the liver before and after gastric bypass.  Obes Surg. 2006;  16(5) 607-611
    CrossrefPubMedGoogle Scholar
  • 203 Dixon J B, Bhathal P S, O'Brien P E. Weight loss and non-alcoholic fatty liver disease: falls in gamma-glutamyl transferase concentrations are associated with histologic improvement.  Obes Surg. 2006;  16(10) 1278-1286
    CrossrefPubMedGoogle Scholar
  • 204 Liu X, Lazenby A J, Clements R H, Jhala N, Abrams G A. Resolution of nonalcoholic steatohepatits after gastric bypass surgery.  Obes Surg. 2007;  17(4) 486-492
    CrossrefPubMedGoogle Scholar
  • 205 Furuya Jr C K, de Oliveira C P, de Mello E S et al.. Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years.  J Gastroenterol Hepatol. 2007;  22(4) 510-514
    CrossrefPubMedGoogle Scholar
  • 206 Flum D R, Dellinger E P. Impact of gastric bypass operation on survival: a population-based analysis.  J Am Coll Surg. 2004;  199(4) 543-551
    CrossrefPubMedGoogle Scholar
  • 207 Sampalis J S, Liberman M, Auger S, Christou N V. The impact of weight reduction surgery on health-care costs in morbidly obese patients.  Obes Surg. 2004;  14(7) 939-947
    CrossrefPubMedGoogle Scholar
  • 208 Adams T D, Gress R E, Smith S C et al.. Long-term mortality after gastric bypass surgery.  N Engl J Med. 2007;  357(8) 753-761
    CrossrefPubMedGoogle Scholar
  • 209 Sjostrom L, Narbro K, Sjostrom C D et al.. Effects of bariatric surgery on mortality in Swedish obese subjects.  N Engl J Med. 2007;  357(8) 741-752
    CrossrefPubMedGoogle Scholar
  • 210 Bray G A. The missing link: lose weight, live longer.  N Engl J Med. 2007;  357(8) 818-820
    CrossrefPubMedGoogle Scholar

Paul D BerkM.D. 

Professor of Medicine, Division of Digestive and Liver Diseases, Columbia University Medical Center, Russ Berrie Medical Science Pavilion

1150 Saint Nicholas Avenue, Room 412, New York, NY 10032

Email: pb2158@columbia.edu

      >